Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia?
AuthorsCooper, Rachel A
Cowan, Richard A
Owens, Susan E
Roberts, Jacqueline K
Hillel, Philip G
Slevin, Nicholas J
Gupta, Nirmal K
Collins, Conor D
AffiliationDepartment of Clinical Oncology, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractThis study was undertaken to determine whether standard salivary gland scintigraphy may be used for the objective assessment of salivary gland sialogogues, in particular oral pilocarpine, in the treatment of post-radiotherapy xerostomia. Nine patients, with xerostomia following radiotherapy to the head and neck region underwent salivary gland scintigraphy with technetium-99m pertechnetate (40 MBq) both before and following 1 month of oral pilocarpine (5 mg tds). For each scan, the percentage uptake in the first 14 min, the peak uptake, time to peak uptake and the percentage of activity excreted following lemon juice stimulation were calculated. The results were correlated with the subjective response as assessed by questionnaire and visual analogue scale. We found no correlation between subjective response and any of the four scan parameters analysed. We could not identify any parameter that predicted those patients who would respond to pilocarpine. In addition, only one parameter, the percentage of activity excreted following stimulation, correlated with previous dose of radiotherapy to the gland. In conclusion, in this study salivary gland scintigraphy did not appear to correlate with or predict response to oral pilocarpine. However, future studies might consider performing salivary gland scintigraphy prior to radiotherapy as well as at differing time points following the commencement of pilocarpine.
CitationDoes salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia? 1999, 26 (3):220-5 Eur J Nucl Med
JournalEuropean Journal of Nuclear Medicine